Scope
NICE guideline NG240, with March 2024 notes, on recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies (from 29 days), children, young people and adults. It covers suspicion and red flags, emergency transfer and pre-hospital antibiotics, hospital investigations including lumbar puncture and neuroimaging, empirical and organism-specific antibiotics, corticosteroids, fluids and intracranial pressure, immunodeficiency and recurrence assessment, and discharge and long-term follow-up. Treatment of newborns and detailed sepsis assessment are covered by other NICE guidelines.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognition, risk factors and safety netting
- Strongly suspect bacterial meningitis when all four features are present: fever, headache, neck stiffness, and altered consciousness or cognition (including confusion or delirium). Strong suspicion is still possible on clinical assessment without the full combination. The more features present, the more likely the diagnosis. [1]
- Strongly suspect meningococcal disease if any of these is present: purpura with lesions larger than 2 mm; a rapidly progressive or spreading non-blanching rash; or meningitis features with a non-blanching rash. Absence of a rash does not exclude it. Examine the whole body, including nappy areas and conjunctivae. Rashes can be harder to see on brown, black or tanned skin. Warn families that a blanching rash can become non-blanching. [1]
- Be on heightened alert for bacterial meningitis (including meningococcal meningitis) in people with any listed risk factor. The list includes: missed meningococcal, Hib or pneumococcal vaccines; reduced or absent spleen function; congenital complement deficiency or acquired inhibition; and being a further or higher education student, especially in large shared accommodation. [1]
- The same heightened-alert list for bacterial meningitis also includes: a family history of meningococcal disease; contact with Hib or meningococcal disease, or time in a meningococcal outbreak area; a previous episode of bacterial meningitis or meningococcal disease; a cerebrospinal fluid leak; and a cochlear implant. [1]
- When people are sent home after assessment, explain which symptoms and changes should prompt return and point them to online information. Ask them to come back if new symptoms appear, existing symptoms worsen or a rash becomes non-blanching. [1]
Transfer and pre-hospital antibiotics
- Transfer anyone with suspected disease to hospital as an emergency, and tell the hospital they will need assessment by a senior clinical decision maker. Do not delay transfer to give antibiotics. Pre-hospital options are IV or IM ceftriaxone or benzylpenicillin: - For strongly suspected meningitis, give them only if a clinically significant transfer delay is likely. - For strongly suspected meningococcal disease, give them as soon as possible unless this delays transfer. - Withhold them if there is severe allergy to either drug. [1]
Hospital investigations
- A senior clinical decision maker should ensure antibiotics start within 1 hour of arrival. In meningococcal disease, take blood tests before antibiotics. In bacterial meningitis, do bloods and lumbar puncture first only if this is safe and causes no clinically significant delay to antibiotics. In either condition, take a bacterial throat swab for meningococcal culture, preferably before antibiotics, and state this purpose on the request form. [1]
- For suspected bacterial meningitis, send: - blood culture - white cell count including neutrophils - CRP, or procalcitonin if CRP is unavailable - blood glucose - whole-blood PCR including meningococcal and pneumococcal targets - an HIV test in line with recommendations 1.10.1 and 1.10.2; for babies, children and young people, testing is considered if they have signs of immunodeficiency or risk factors for HIV [1]
- Neuroimaging is not routine before lumbar puncture. Perform imaging if there are risk factors for an evolving space-occupying lesion, or signs that might indicate raised intracranial pressure: new focal neurological features (including seizures or posturing), abnormal pupillary reactions, or a GCS of 9 or less or a progressive and sustained or rapid fall in level of consciousness. Take bloods, give antibiotics and stabilise the person before imaging. [1]
- Do not perform lumbar puncture if there is extensive or rapidly spreading purpura, or infection at the puncture site. Also withhold it, and follow the imaging recommendation, if there are risk factors for an evolving space-occupying lesion or signs that might indicate raised intracranial pressure. These signs are new focal neurological features (including seizures or posturing), abnormal pupillary reactions, or a GCS of 9 or less or a progressive and sustained or rapid fall in level of consciousness. [1]
- Treat and stabilise problems such as uncontrolled seizures before lumbar puncture. If antibiotics have already started, perform lumbar puncture as soon as it is safe. Measure blood glucose immediately before the procedure so that the CSF to blood glucose ratio can be calculated. [1]
- For suspected bacterial meningitis, CSF tests should include cell counts with differential, Gram stain, culture and sensitivities, and PCR for relevant pathogens. Cell counts, protein and glucose should be available within 4 hours of lumbar puncture. [1]
- When interpreting CSF results, allow for earlier antibiotics and for higher normal thresholds in babies under 3 months. If results are abnormal, also consider viral, mycobacterial, fungal or non-infectious causes. A normal CRP, procalcitonin or white cell count alone does not rule out either bacterial meningitis or meningococcal disease. [1]
Antibiotics and meningococcal treatment in hospital
- Give IV antibiotics as soon as bacterial meningitis is suspected, within 1 hour of arrival, after blood samples. Perform lumbar puncture before antibiotics only if this is safe and causes no clinically significant delay. - Organism unknown: use ceftriaxone at the highest BNF/BNFC doses or per local guidance; consider cefotaxime if ceftriaxone is contraindicated. - Listeria risk factors: add IV amoxicillin. - IV aciclovir is not routine unless herpes simplex encephalitis is strongly suspected. - Ceftriaxone is incompatible with calcium-containing solutions. [1]
- Seek infection specialist advice in every case of bacterial meningitis. This matters especially after recent travel outside the UK with possible resistance, or with cephalosporin-resistant Enterobacterales colonisation. If CSF suggests bacterial meningitis but blood culture and whole-blood PCR are negative, treat for 10 days. Then stop if recovered; if not, seek specialist advice. [1]
- Use high-dose ceftriaxone for pneumococcal and Hib meningitis. - Pneumococcal: stop after 10 days if recovered; otherwise seek specialist advice. - Hib: get specialist advice at the start. Stop after 7 days if recovered, or continue to 10 days in total if not. Seek further advice if still not recovered after 10 days. [1]
- Stopping points if recovered, with specialist advice if not: - Group B streptococcal meningitis: get specialist advice at the start; stop after 14 days. - Enterobacterales: get specialist advice on meropenem while awaiting sensitivities; stop after 21 days. - Neisseria meningitidis meningitis: stop after 5 days. [1]
- Treat Listeria meningitis with IV amoxicillin or ampicillin for 21 days. Get specialist advice on adding IV co-trimoxazole for the first 7 days; this was off-label in March 2024. [1]
- For meningitis with antibiotic allergy, ask about the reaction and get specialist advice, particularly in pregnancy. - Not severe: consider ceftriaxone or cefotaxime, adding co-trimoxazole if there are Listeria risk factors. - Severe: consider chloramphenicol, combined with co-trimoxazole if there are Listeria risk factors. [1]
- Treat suspected or confirmed meningococcal disease with IV ceftriaxone. Stop after 5 days if recovered; otherwise seek specialist advice. Non-severe allergy still permits ceftriaxone; for severe allergy, get specialist advice and consider chloramphenicol. Corticosteroids are not routine in meningococcal disease, but consider low-dose replacement corticosteroids for meningococcal septic shock not responding to high-dose vasoactive agents. [1]
Dexamethasone, fluids and intracranial pressure in bacterial meningitis
- Dexamethasone in bacterial meningitis: - Over 3 months, strongly suspected or confirmed: give IV dexamethasone. - 28 days to 3 months: get infection specialist advice. - Once the organism is found, continue for pneumococcus or Hib and stop for all other organisms. - If no organism is found, get infection specialist advice on whether to continue. [1]
- Give the first dexamethasone dose with or before the first antibiotic dose if possible, without delaying antibiotics. If dexamethasone is delayed less than 12 hours after antibiotics start, give it as soon as possible; beyond 12 hours, decide with an infection specialist whether it is still likely to help. [1]
- Avoid routine fluid restriction below maintenance needs; give maintenance fluids orally or enterally if tolerated. Never use glycerol, and do not routinely use other osmotic agents. Invasive intracranial pressure monitoring is not routine; seek specialist advice on monitoring if there are features of raised pressure or hydrocephalus. [1]
- With signs of raised intracranial pressure and concern about brain herniation, consider osmotic agents (not glycerol) as a temporary measure. Get urgent critical care advice for adults, and urgent paediatric critical care advice for babies, children and young people. [1]
Immunodeficiency and recurrence
- HIV testing and immunology review: - Test adults with either condition for HIV. - Consider HIV testing in babies, children and young people (not adults) with either condition if they have signs of immunodeficiency or HIV risk factors. - Refer babies, children and young people with pneumococcal meningitis for primary immunodeficiency assessment. - After a recurrent episode, test for HIV at all ages and arrange specialist review to agree preventive measures. - For recurrent bacterial meningitis, seek radiological advice on investigating a CSF leak. [1]
Discharge and long-term follow-up
- Offer audiological assessment within 4 weeks of being well enough to test, preferably before discharge. Offer children, young people and adults with severe or profound deafness an urgent cochlear implant assessment. Arrange review 4 to 6 weeks after discharge: with a paediatrician for babies, children and young people, or a hospital doctor for adults. Babies under 12 months need a paediatric review 1 year after discharge. For babies, children and young people, community child development services should assess neurodevelopmental risk for at least 2 years after discharge. Refer people on anti-epileptic drugs for a medicines review 3 months after discharge. [1]
Limitations and use
- Treatment of bacterial meningitis in newborn babies in hospital is not covered and is deferred to the NICE neonatal infection guideline.
- Detailed sepsis assessment, fever in under 5s and tuberculous meningitis are deferred to other NICE guidelines.
- Antibiotic doses are not specified; the guideline refers to the BNF/BNFC or local antimicrobial guidance.
- Co-trimoxazole and all dexamethasone uses described were off-label as of March 2024.
- Rationale, research recommendations and committee discussion chapters were not part of the reviewed source, and flowcharts were represented only by alternative text.
- Guidance assumes UK services and regulators (for example DVLA, MHRA, UK public health guidance); applicability elsewhere is not addressed.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 19 March 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.